国产99久久精品_欧美日本韩国一区二区_激情小说综合网_欧美一级二级视频_午夜av电影_日本久久精品视频

DiscoveRx   
成立于2000年的 DiscoveRx 是一家私人持股，風(fēng)險(xiǎn)投資支持的公司，總部設(shè)在加州弗里蒙特，在英格蘭伯明翰設(shè)立辦事處。公司率先發(fā)現(xiàn)beta-糖苷酶片段互補(bǔ)在生物化學(xué)和以細(xì)胞為基礎(chǔ)的實(shí)驗(yàn)中對(duì)研發(fā)的作用，在這方面擁有豐富的知識(shí)產(chǎn)權(quán)。DiscoveRx 致力于開(kāi)發(fā)和新型方法商業(yè)化，用以研究 Gapers，室壁不隨意運(yùn)動(dòng)和其他主要的藥物靶標(biāo)類(lèi)。許多創(chuàng)新產(chǎn)品在全球制藥和生物技術(shù)新藥篩選實(shí)驗(yàn)室中廣泛應(yīng)用

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, California and Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation (EFC) in HitHunter? biochemical and PathHunter? cell based assays for discovery research. In addition to the EFC platform, DiscoveRx also holds extensive intellectual property for its second core technology, an in vitrobinding assay platform called KINOMEscan?. Utilizing these two proprietary platforms, DiscoveRx has developed and commercialized industry leading panels of GPCR, Kinase, and NHR assay solutions for drug discovery research. Many of DiscoveRx's innovative solutions have been widely adopted in pharmaceutical, academic and biotechnology laboratories worldwide.